Animal Orthopedic Diseases Stem Cell Therapy Market

The global animal orthopedic diseases stem cell therapy market was valued at USD 280.0 million in 2025 and is estimated at USD 327.7 million in 2026. Revenue is forecast to reach USD 1,154.6 million by 2034, representing a 17.0% CAGR during 2026–2034.

Veterinary stem cell treatment for orthopedic disease encompasses living mesenchymal stromal cell products and veterinarian-directed processing services used for osteoarthritis, tendon damage, ligament injury and selected bone or joint conditions in dogs, horses and other animals. The revenue boundary includes licensed cell medicines, in-clinic or laboratory cell preparation, veterinary procedure fees directly attributable to cell delivery, cell storage and contract manufacturing for orthopedic programs. Platelet-rich plasma, hyaluronic acid, conventional anti-inflammatory drugs and unrelated cell therapies are excluded.

The European Medicines Agency lists DogStem for canine osteoarthritis, HorStem for equine musculoskeletal disease and Arti-Cell Forte for equine joint disease. EquiCord manufactures DogStem and HorStem using equine umbilical-cord-derived mesenchymal cells. In contrast, the U.S. Food and Drug Administration states that it has no approved animal cell-and-tissue-based products, and its risk-based review or investigational pathways do not constitute efficacy approval. The distinction changes how companies can advertise, distribute and finance therapies in different jurisdictions.

VetStem reported nearly 43,000 treatments derived from more than 17,000 processed animal samples by September 2026, reflecting an established autologous service business. Its StemStat Ortho program remains under development for canine osteoarthritis. Gallant reported favorable canine osteoarthritis pilot outcomes in May 2026 and expanded conditional-approval eligibility, but its product remains investigational. These programs illustrate the coexistence of patient-specific processing revenue with pipeline investment in standardized donor-cell products.

A multicenter randomized study of 80 dogs with osteoarthritis reported improvements in gait and veterinary orthopedic assessments after equine umbilical-cord mesenchymal cell injection. A separate 2023 study followed 35 dogs receiving intravenous equine-derived cells and reported tolerability and changes in pain and lameness measures. Trial designs, follow-up periods and treatment routes vary substantially, so commercial adoption depends on stronger comparative evidence, reproducible cell manufacturing and informed veterinary consent rather than claims that cartilage repair is established.

Source: FDA Center for Veterinary Medicine; EMA DogStem; VetStem September 2026; Canine randomized trial.

Revenue includes veterinary orthopedic stem-cell medicines, autologous processing and orthopedic delivery services, as well as directly attributable cell-manufacturing and banking contracts, measured without counting the same procedure twice.

Drivers Impact Analysis*

Restraints Impact Analysis*

*CAGR contribution shows the percentage points each factor adds to or removes from the 17.0% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

Canine joint disease sustains recurring demand for specialty interventions

Dogs with naturally occurring osteoarthritis remain an important clinical population for regenerative-cell trials. The randomized study of 80 dogs treated with equine umbilical-cord cells evaluated gait, orthopedic examination and owner-reported outcomes at weeks 4, 8 and 12. Veterinarians use these measurements alongside imaging, rehabilitation and conventional analgesia when discussing cell interventions. The expanding U.S. pet-owning base, which APPA counted at 71 million dog-owning households in 2025, creates a broad referral population even when only a minority of patients receive specialized orthopedic care.

European authorisations create differentiated commercial routes

EMA records DogStem, HorStem and Arti-Cell Forte as veterinary stem-cell medicines for musculoskeletal indications. EquiCord distributes HorStem through its Spanish GMP facility, while D - mes Pharma markets DogStem to British veterinary prescribers. A product-specific authorization enables consistent labeling and batch release, but it does not remove the need for veterinarian selection, owner consent and adverse-event monitoring. In the United States, FDA guidance continues to distinguish investigational animal cell products from approved new animal drugs, making transatlantic commercialization dependent on separate regulatory dossiers.

Off-the-shelf donor cells could reduce procedure complexity

Autologous processing requires tissue collection, shipping, laboratory preparation and a subsequent treatment appointment. Gallant is developing uterine-derived allogeneic cells intended for intravenous delivery, while VetStem is advancing StemStat Ortho as an off-the-shelf canine osteoarthritis candidate. Gallant announced a February 2026 cold-chain fulfillment agreement with MWI Animal Health, and VetStem reported additional development funding in March 2025. Centralized donor-cell manufacturing may shorten clinic workflows, although cell identity, potency, stability and clinical effectiveness must still satisfy applicable regulators.

Manufacturing and evidence requirements constrain treatment adoption

FDA guidance #218 treats qualifying veterinary cell products as new animal drugs, and subsequent guidance addresses current good manufacturing practice and donor eligibility. In the United Kingdom, the Veterinary Medicines Directorate published a May 2026 application route for animal stem-cell centers conducting autologous work. These requirements add process controls, testing and specialist staffing costs. Comparative trials are also costly because canine pain assessments, lameness scoring and owner observations can produce different effect estimates, while long-term structural joint repair remains insufficiently established.

Pet spending and referral access shape affordability

APPA reported USD 41.0 billion in U.S. veterinary care and product sales for 2025, while the Brazilian pet industry association ABEMPET recorded BRL 7.7 billion in veterinary services for 2024. These are broad spending indicators rather than stem-cell therapy revenue. Owner payment, travel to specialty clinics, sedation and repeat examinations raise the total treatment bill. A 2026 Gallant study announcement reported improved owner-assessed outcomes in treated dogs, but reimbursement decisions and veterinarian recommendations still depend on product status and evidence quality.

Source: FDA CVM; EMA veterinary EPARs; APPA; VetStem; Gallant; UK Veterinary Medicines Directorate.

Veterinary suppliers invest in allogeneic orthopedic pipelines

Xintela signed an April 2025 collaboration and license agreement with EQGen Biomedical for EQSTEM, initially targeting equine joint disease. The agreement included a USD 1 million license fee and USD 3 million in EQGen shares, subject to financing, with additional development economics. In May 2026, Gallant described canine osteoarthritis pilot data and FDA eligibility for an expanded conditional-approval pathway. These programs move research spending toward banked donor-cell formulations, with manufacturing quality and clinical endpoints central to future commercialization.

Equine and canine indications demand different delivery systems

HorStem and Arti-Cell Forte serve equine musculoskeletal indications, while DogStem is directed at canine osteoarthritis. Horse tendon and joint injuries involve different loading patterns, rehabilitation schedules and treatment costs than canine hip or elbow disease. Magellan describes both canine arthritis treatments and equine tendon or ligament applications from its Australian operation. Product selection therefore depends on species-specific labeling, dose and route, rather than transferring results from dogs to horses or treating all mesenchymal cells as interchangeable.

Safety evaluation expands beyond immediate injection reactions

A 2023 randomized study in 24 healthy police dogs examined local, systemic and immune responses after single and repeated intra-articular mesenchymal cell injections. Researchers compared equine umbilical-cord cells with canine adipose-derived cells and placebo, reporting no adverse events under the study conditions. FDA donor-eligibility guidance and UK manufacturing authorization requirements address additional risks arising from collection, storage and handling. Long-term pharmacovigilance remains important because repeated dosing and immunologic responses require observation beyond short controlled trials.

Referral clinics connect rehabilitation with cell-based interventions

VetStem reports veterinary use of autologous adipose-derived cells for dogs, cats and horses, with cell processing performed centrally after tissue collection. EquiCord ships HorStem from its Spanish manufacturing site to European distributors. Both models require trained veterinary teams to diagnose disease, deliver cells and manage recovery. Physiotherapy, controlled exercise and established pain management remain part of orthopedic care, so the stem-cell procedure is generally positioned within a wider treatment plan rather than as a replacement for every surgical or medical option.

Regulatory language differentiates approved and investigational products

FDA states that no animal cell-and-tissue-based products have received U.S. approval, while EMA records authorization histories for DogStem, HorStem and Arti-Cell Forte. Gallant identifies its canine osteoarthritis program as investigational despite conditional-pathway eligibility. VetStem likewise describes StemStat Ortho as a candidate seeking conditional approval. Clear labeling reduces the risk of confusing a risk-reviewed product, a clinical study, an approved European medicine and an unapproved U.S. processing service when veterinarians counsel owners. In 2026, the UK VMD also clarified site authorization procedures for autologous animal stem-cell centres, adding another distinction between clinical services and authorized veterinary medicinal products.

Orthopedic veterinary stem-cell approaches differ in cell source, species, manufacturing controls and route of administration. Licensed European medicines and U.S. investigational programs therefore require separate clinical and regulatory interpretation.

Autologous processing begins with tissue from the recipient animal, typically adipose tissue, followed by laboratory isolation and delivery to the veterinarian. VetStem reports almost 43,000 treatments by September 2026, illustrating the operational scale possible without a standardized donor-cell medicine. Because each batch comes from an individual patient, processing schedules, sample quality and logistics affect throughput and cost.

Allogeneic and xenogeneic programs rely on donor selection and repeatable cell expansion. The 80-dog randomized osteoarthritis trial studied equine-derived mesenchymal cells, whereas Gallant is testing uterine-derived donor cells in dogs. Investigators assess lameness, owner-reported pain and functional mobility; positive results from one cell source do not automatically establish efficacy for another formulation, injection route or orthopedic diagnosis.

EMA records approved veterinary stem-cell medicines in Europe, while FDA maintains a different regulatory position in the United States. Product labels must be checked by country, indication and species. Veterinary teams should explain that an investigational treatment or a risk-reviewed animal cell product is not equivalent to an FDA-approved therapy, and that routine orthopedic pain management remains necessary when a stem-cell intervention is not indicated.

Autologous, allogeneic and xenogeneic therapies differ by the relationship between cell donor and recipient. The classification is mutually exclusive at the administered cell-product level and separates clinic-specific processing from banked donor supply.

The type mix may shift toward donor-cell products as manufacturing and regulatory dossiers mature, while autologous services continue serving veterinarians that already use patient-specific processing. The 2023 canine safety trial compared equine-derived and canine-derived cells under a randomized design, providing a concrete basis for evaluating cross-species immune response. D - mes Pharma supplies DogStem through a prescription channel in Britain, whereas VetStem returns processed cells for individual North American patients.

The four orthopedic indication groups are assigned according to the primary treated condition. Osteoarthritis is distinguished from tendon and ligament injury, developmental joint disorders, and bone or cartilage defects to avoid double-counting one procedure.

Bone and cartilage defects represent a smaller experimental or specialist group where structural restoration is a more demanding endpoint than short-term pain reduction. The 2022 multicenter canine trial evaluated hip and elbow osteoarthritis rather than all musculoskeletal disorders. Magellan Veterinary Stem Cells describes equine tendon and ligament research using mesenchymal cells supplied through its Australian laboratory program. Those differences affect the clinical outcome measures selected by veterinarians, including gait scoring, joint function and ultrasound assessment of injured soft tissue.

Species-level demand reflects the incidence of joint disease, the value of animal mobility and access to specialty veterinary hospitals. Dogs and horses account for the clearest commercial and clinical evidence, while cats and other species remain narrower treatment groups.

Species-specific labeling and veterinary training restrict substitution between canine, equine and feline products even when the same broad cell class is used. Gallant’s April 2026 feline pilot program reported owner-assessed quality-of-life outcomes, whereas its May canine announcement discussed canine osteoarthritis endpoints. EquiCord’s licensed equine-derived medicines demonstrate that the donor species can differ from the recipient species without making every cross-species cell formulation clinically equivalent.

The service-channel axis assigns revenue to the organization responsible for the primary orthopedic cell-therapy encounter. It distinguishes referral hospitals, independent clinics, central processing laboratories and equine practices.

Equine referral practices remain a distinct service channel because horse handling, joint procedures and rehabilitation workflows differ materially from companion-animal clinics. VetStem’s September 2026 processing milestone documents a central-laboratory workflow, while EquiCord describes GMP production and medicalized European distribution. Gallant’s February 2026 MWI partnership targets ultra-low-temperature transport, a distinct requirement for standardized frozen donor-cell products compared with tissue-collection services at individual clinics. Veterinary Medicines Directorate guidance published in May 2026 also specifies authorization requirements for centers handling autologous animal cells in Great Britain, influencing laboratory and clinic investment.

Regional adoption depends on veterinary licensing, specialty-care capacity, companion-animal spending and the availability of licensed or investigational cell therapies. North America leads the modeled base-year revenue share, while Europe has several specifically authorized veterinary stem-cell medicines.

Veterinary access is shaped by product approval, availability of cell processing and the total cost of orthopedic diagnosis and follow-up. Licensed European medicines and U.S. investigational services require different procurement pathways.

FDA advises U.S. pet owners that no animal cell-and-tissue-based products have received agency approval. It distinguishes risk-based product review from an approval of safety and effectiveness for an animal drug. For developers, FDA guidance #218 and related donor-eligibility and manufacturing documents describe the regulatory obligations that apply to qualifying animal cell therapies. Clinic consent materials should not characterize an investigational canine osteoarthritis candidate as approved.

The UK Veterinary Medicines Directorate published an animal stem-cell centre authorization application in May 2026 for autologous treatments in non-food animals. The application covers collection, storage, processing, production and administration activities and requires site information and supporting manufacturing documentation. In the EU, DogStem, HorStem and Arti-Cell Forte have distinct veterinary authorization histories, and clinicians must use the approved species and indications.

VetStem central processing requires collection of animal adipose tissue before cells are returned for administration, whereas standardized donor-cell medicines aim to reduce the preparation burden at individual clinics. Gallant and MWI Animal Health announced an ultra-low-temperature veterinary fulfillment arrangement in February 2026, showing the importance of cryogenic logistics for future products. Owner payment, specialty referral travel and post-procedure assessment can remain significant even when cell manufacturing becomes more efficient.

Source: FDA ACTP Q&A; UK VMD.

Regulatory oversight differs sharply across markets, and clinical-stage progress must not be mistaken for authorization. European orthopedic veterinary cell medicines provide approved precedents, while U.S. programs remain subject to FDA review.

EMA’s Arti-Cell Forte product record identifies chondrogenic-induced equine allogeneic peripheral-blood-derived mesenchymal cells, while HorStem and DogStem use equine umbilical-cord-derived cells. Each authorization applies to its specified veterinary medicine and indication. The EMA also refused Horse Allo 20 for equine osteoarthritis after reviewing its evidence, demonstrating that stem-cell technology does not guarantee a positive regulatory outcome.

In the United States, FDA states that no animal cell-and-tissue-based products have been approved. Its guidance #218 addresses animal cell products that meet the definition of new animal drugs, while additional documents cover manufacturing and donor eligibility. Gallant’s May 2026 announcement concerned pathway eligibility and a canine pilot study, not conditional approval. VetStem’s March 2025 announcement concerned financing for StemStat Ortho development rather than a completed authorization.

Brazilian veterinary authorities established professional rules for stem-cell use in animals in 2020. The UK added updated application guidance for animal stem-cell centers in 2026. These examples show that the market includes product authorizations, facility authorizations and professional-practice controls, which should be evaluated separately when comparing geographic access, supplier claims and clinical availability. The EMA refusal of Horse Allo 20 further shows that an application may fail when efficacy evidence does not meet the agency’s standards, even when a similar cell technology has been authorized in another product.

Competition includes authorized European cell-medicine manufacturers, North American autologous processing businesses and clinical-stage developers seeking standardized donor-cell products. Product status, species-specific evidence, manufacturing quality and veterinary distribution determine supplier positioning.

Magellan Veterinary Stem Cells offers Australian programs for canine degenerative joint disease and equine soft-tissue injury, although its website currently reports a temporary suspension of new veterinary orders linked to human-trial manufacturing preparations. That interruption highlights the commercial importance of capacity planning and separate manufacturing lines for veterinary products.

CelulaVet advertises stem-cell treatment services for horses and dogs, while Vetherapy describes development of veterinary regenerative-cell therapies. Their commercial positioning is narrower than that of multinational animal-health pharmaceutical groups. The market remains fragmented because a clinic-specific autologous procedure is not directly interchangeable with a licensed batch-manufactured veterinary cell medicine.

Gallant raised USD 18 million in Series B financing in June 2025 to support its veterinary cell pipeline, which includes canine and feline osteoarthritis. Xintela disclosed a USD 1 million EQGen license fee and USD 3 million in shares, subject to financing. These transactions finance development and manufacturing capability; they are not evidence of equal-sized sales for currently approved orthopedic medicines. EquiCord’s established authorized medicines and Magellan’s manufacturing pause also show that clinical trial progress, licensed-product distribution and operational capacity need to be assessed independently when comparing suppliers. The competitive set excludes hospitals because they deliver care rather than develop or manufacture proprietary cell platforms.

• VetStem, Inc.
• Gallant
• EquiCord S.L.
• D - mes Pharma
• Magellan Veterinary Stem Cells
• Xintela AB
• EQGen Biomedical
• eQcell Inc.
• CelulaVet
• Vetherapy

The animal orthopedic diseases stem cell therapy market is projected to rise from USD 327.7 million in 2026 to USD 1,154.6 million in 2034, equivalent to 17.0% annual growth over the forecast interval.

Canine osteoarthritis should remain the largest indication as established veterinary referral networks and aging pet populations sustain demand. The 80-dog randomized trial of equine-derived cells and Gallant’s 2026 pilot announcements provide clinical-development evidence, although different formulations and endpoints prevent direct equivalence. The growth forecast assumes additional specialist clinics adopt cell procedures and that authorized medicines reach more prescribers where local regulations permit.

Autologous therapy retains an installed processing base, supported by VetStem’s disclosed treatment history. Donor-cell products could capture a larger portion of new procedures if manufacturing standards, stability and product-specific efficacy requirements are satisfied. The EU already offers examples of authorized equine and canine cell medicines, while U.S. programs remain investigational under FDA rules. A regulatory decision therefore can change revenue timing more sharply than ordinary clinic expansion.

European demand should benefit from medicine-specific authorizations and veterinary specialty networks, while North American revenue continues to draw on processing services and pipeline investment. Australian capacity constraints and Latin American owner-payment sensitivity create different barriers. Brazil’s veterinary professional regulations provide a practice framework, but they do not by themselves guarantee broad access to standardized cell products or reimbursement for orthopedic procedures.

Key forecast risks include manufacturing deviations, adverse-event signals, trial results that do not reproduce earlier findings, and costs that keep owners on conventional analgesia or surgery. Upside could come from stronger blinded evidence, reliable repeatable donor-cell supply and distribution partnerships with veterinary wholesalers. Companies able to document species-specific outcomes and comply with local authorization rules are better positioned to convert clinical referrals into sustained treatment revenue.

Coverage includes veterinary cell products, orthopedic processing services, clinic distribution, animal species, regulatory pathways and geographic access.